The Viral Interferon Regulatory Factors of KSHV: Immunosuppressors or Oncogenes? by Sarah R. Jacobs & Blossom Damania
REVIEW ARTICLE
published: 17 June 2011
doi: 10.3389/ﬁmmu.2011.00019
The viral interferon regulatory factors of KSHV:
immunosuppressors or oncogenes?
Sarah R. Jacobs and Blossom Damania*
Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Edited by:
Murali Krishna Kaja, University of
Washington, USA
Reviewed by:
Fanxiu Zhu, Florida State University,
USA
Michael Lagunoff, University of
Washington, USA
*Correspondence:
Blossom Damania, Lineberger Cancer
Center, University of North Carolina at
Chapel Hill, 450West Drive, Campus
Box 7295, Chapel Hill, NC 27599,
USA.
e-mail: damania@med.unc.edu
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a large double-stranded DNA gamma-
herpesvirus, and the etiological agent for three human malignancies: Kaposi’s sarcoma,
primary effusion lymphoma, and multicentric Castleman’s disease. To establish and main-
tain infection, KSHV has evolved unique mechanisms to evade the host immune response.
Cellular interferon regulatory factors (IRFs) are a critical part of the host anti-viral immune
response. KSHV encodes four homologs of IRFs, vIRF1–4, which inhibit the activity of their
cellular counterparts. vIRF1, 2, and 3 have been shown to interact directlywith cellular IRFs.
Additionally, the vIRFs have other functions such as modulation of Myc, p53, Notch, trans-
forming growth factor-β, and NF-κB signaling. These activities of vIRFs may contribute to
KSHV tumorigenesis. KSHV vIRF1 and vIRF3 have been implicated as oncogenes, making
the understanding of KSHV vIRF function vital to understanding KSHV pathogenesis.
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INTRODUCTION
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known
as human herpes virus 8, is a double-stranded, DNA tumor
virus belonging to the gammaherpesvirus subfamily. KSHV has
been implicated as the causative agent for multiple human can-
cers including Kaposi’s sarcoma (KS), multicentric Castleman’s
disease (MCD), and primary effusion lymphoma (PEL; Wen
and Damania, 2010). KSHV-associated cancers are prevalent in
immunocompromised individuals, such as transplant recipients
and HIV-infected individuals (Angeletti et al., 2008; Wen and
Damania, 2010). Like all herpesviruses,KSHV establishes life-long
latency in a variety of cell types including B cells, macrophages,
endothelial cells, and monocytes in vivo (Boshoff et al., 1995;
Blasig et al., 1997; Sirianni et al., 1998; Monini et al., 1999; Wu
et al., 2006).
Similar to other herpesviruses, KSHV establishes infection and
exists primarily in the latent state. In a latent infection, KSHV
is dormant and persists for the lifetime of the host through
viral genome tethering to the host chromosome via the latency-
associated nuclear antigen (LANA;Ballestas et al., 1999;Cotter and
Robertson, 1999; Barbera et al., 2006; Verma et al., 2007). During
latency, only a subset of viral genes is actively transcribed. In con-
trast, de novo infection results in viral lytic replication for approx-
imately 72–96 h, prior to the establishment of latency (Krishnan
et al., 2004). During the lytic cycle, the viral genome is replicated
and progeny virions are released from the cell and can subse-
quently infect neighboring cells. KSHV can also be induced to
undergo lytic replication following reactivation by superinfection
with another virus (Gregory et al., 2009) or chemical treatment
with 12-O-tetradecanoyl-phorbol-13-acetate (Renne et al., 1996).
In order to establish infection and maintain latency, KSHV
must evade the host immune response. The virus encodes a vari-
ety of immune evasion genes as previously reviewed (West and
Damania, 2010). One mechanism through which KSHV evades
immunity is by encoding viral homologs of cellular genes that
augment or subvert the function of their cellular counterparts.
These genes include viral interleukin-6 (IL-6), a viral form of
the inﬂammatory cytokine IL-6 (Neipel et al., 1997a), vBcl-2, a
viral protein similar to Bcl-2, which prevents apoptosis (Cheng
et al., 1997; Huang et al., 2002), and four viral homologs of cellu-
lar interferon regulatory factors (IRFs; Russo et al., 1996; Neipel
et al., 1997b; Cunningham et al., 2003), which will be the focus of
this review.
Interferon (IFN) is the primary response of a host cell to viral
infection and protects the host by inhibiting viral replication,
increasing activation of antigen presenting cells, inhibiting cell
proliferation, and promoting apoptosis of the infected cell (Pestka
et al., 2004). Cellular IRFs mediate part of the IFN response ini-
tiated by the host innate immune system and are transcription
factors that bind to and activate interferon-responsive promoters.
Nine mammalian IRFs operate in coordination to elicit distinct
immune responses (Tamura et al., 2008). Activation of the IFN
response by viral infection or pathogen detection leads to phos-
phorylation,dimerization, andnuclear translocation of IRFs. IRF3
and IRF7 are critical for transcription of type I interferons, IFN
α and β (Tamura et al., 2008). IRF-mediated transcription creates
an anti-viral state characterized by increased antigen presenta-
tion, degradation of RNA, cessation of protein processing, and
induction of apoptosis (Alshariﬁ et al., 2008).
Additionally, IRF familymembers also play a role in cell growth
and proliferation. This regulation, combinedwith cell survival sig-
naling, has implicated IRFs in tumor formation (Tamura et al.,
2008). For example, IRF1 deﬁciency exacerbated tumor predispo-
sitions (Nozawa et al., 1999), and constitutively active IRF3 leads
to apoptosis (Heylbroeck et al., 2000). Furthermore, IRF3 medi-
ates cell death in response to Sendai virus infection and apoptosis
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can be blocked by expression of a dominate negative form of IRF3
(Heylbroeck et al., 2000).
HOMOLOGY AND EXPRESSION OF vIRFs
Examination of the KSHVgenome identiﬁed the presence of genes
that showed similarity to cellular IRFs (Russo et al., 1996). It was
subsequently determined that three of these viral genes, vIRF1,
2, and 3, blocked IFN signaling (Lee et al., 2009a; Figure 1). The
less studied vIRF4 has not yet been shown to affect IFN signaling,
although it shares other functions with vIRF1, 2, and 3 such as
inhibition of p53 transcription (Lee et al., 2009b; Table 1). KSHV
vIRF1, 2, 3, and 4 are encoded by ORFs K9, K11 and K11.1, K10.5
and K10.6, and K10, respectively (Figure 2 and Table 1). vIRF1
is a lytic gene (Zimring et al., 1998; Burysek et al., 1999a). How-
ever, it was found to be transcribed in latently infected KS cells as
well (Dittmer, 2003). vIRF1 is also expressed in PEL cells includ-
ing BCBL-1, BCP-1, and BC-1 cells where expression increased
following viral reactivation by chemical induction (Moore et al.,
1996; Sarid et al., 1998; Inagi et al., 1999). Lytic expression of
vIRF1 in PEL cells required new protein synthesis (Wang et al.,
2001). vIRF1 levels peak 48 h after TPA treatment, and the protein
has a 3-h half life (Pozharskaya et al., 2004). Similarly, vIRF2 has
been mapped as a lytic gene by DNA array and cluster analysis of
PEL cells (Jenner et al., 2001). vIRF3 was originally discovered as a
latent gene and is also known as LANA2 (Rivas et al., 2001). Unlike
vIRF1, vIRF3 expression is not induced during lytic reactivation
of PEL cells (Wies et al., 2008). vIRF3 is expressed in nearly all PEL
cell lines and in the majority of MCD tumors, but does not appear
to be highly expressed in KS (Rivas et al., 2001). vIRF4 expression
can be induced by TPA and is expressed mostly in the nucleus
(Katano et al., 2000; Kanno et al., 2006).
During latency vIRF1 is localized to pro-myelocytic leukemia
(PML) bodies (Pozharskaya et al., 2004), nuclear granules identi-
ﬁed by the presence of the PML protein and associated with the
FIGURE 1 | Kaposi’s sarcoma-associated herpesvirus vIRFs bind to
cellular proteins, block transcription, and interfere with interferon and
cellular signaling pathways. Viral infection activates cellular IRFs, including
IRF1, 3, 5, and 7 to initiate IFN transcription. Binding of cellular IRFs by vIRF1
or vIRF3 results in a blockade of IFNα, β, and γ transcription. vIRF1 inhibits
type I IFN transcription by binding the CBP/p300 transcriptional coactivator
and inhibiting its activity. Viral infection also induces NF-κB transcription that is
decreased by vIRF3. vIRF1, 3, and 4 inhibit p53 transcription and impede
p53-mediated cell death. Other cell death processes affected by vIRFs include
vIRF1 binding to GRIM19, vIRF3 interaction with 14-3-3 and FOXO3a, vIRF1
and 2 blockade of CD95L production, and vIRF1-mediated nuclear localization
of Bim. In addition to deregulating immune responses and cell death, vIRFs
have other roles such as vIRF3 increasing Myc and HIF-1α transcription and
blocking expression of MHC II. vIRF1 blocks TGF-β signaling through binding
to Smad3 and Smad4 and vIRF4 binding to the Notch transcription factor,
CSL/CBF1 to inhibit activation of Notch target genes.
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Table 1 | Summary of the location, expression, cellular binding partners, and cellular pathways modulated by the KSHV vIRFs.
vIRF1 vIRF2 vIRF3 vIRF4
Genomic locus K9 K11 and K11.1 K10.5 and K10.6 K10
Lytic/latent Lytic Lytic Latent Lytic
Known interacting partners IRF1, IRF3 IRF1, IRF2, IRF8 IRF3, IRF5, IRF7 CBF1
p300/CBP RelA p300/CBP
p53 p300 IKKβ
GRIM19 PKR MM-1α
Bim 14-3-3
FOXO3a
HIF-1α
Modulation of cellular pathways IFN IFN IFN p53
p53 AICD NF-κB Notch
TGF-β p53
Apoptosis Myc
AICD Apoptosis
FIGURE 2 | Map of vIRF gene locus in the KSHV genome.The KSHV vIRF genes are encoded by open reading frames K9 (vIRF1), K11 and K11.1 (vIRF2),
K10.5 and 10.6 (vIRF3), and K10 (vIRF4).
regulation of oncogenesis, cell senescence, and anti-viral defenses
(Lallemand-Breitenbach and de The, 2010). The vIRF2 protein
is present in both the cytoplasm and nucleus in a diffused pat-
tern prior to stimulation of the IFN response (Areste et al., 2009).
Activation of the anti-viral response results in enhanced punctate
expression in the cytoplasm (Areste et al., 2009). Similarly, vIRF3
is localized to the nucleus in a ﬁne granular pattern (Rivas et al.,
2001).
Each cellular IRF contains a well-conserved N-terminal DNA-
binding domain (DBD) of approximately 120 amino acids includ-
ingﬁve conserved tryptophan repeats (Takaoka et al., 2008). KSHV
vIRFs share limited homology with the N-terminal DBD of cel-
lular IRFs, but lack several of these crucial tryptophan residues
(Takaoka et al., 2008; Figure 3). This renders the vIRFs incapable
of binding cellular DNA (Flowers et al., 1998; Zimring et al., 1998;
Tamura et al., 2008). Close examination of vIRF1 reveals that it has
13% homology to human IRF family members, much of which is
localized to the DBD region, and shows similarity to the IRF bind-
ing motif found in IRF8/ICSBP (Russo et al., 1996; Zimring et al.,
1998). The cellular proteins that share the most similarity to the
KSHV vIRFs by NCBI BLASTP analysis are IRF4 and IRF8/ICSBP
(National Center for Biotechnological Information, http://blast.
ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&BLAST_PROGR
AMS=blastp&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=
on&LINK_LOC=blasthome).
vIRF INHIBITION OF IMMUNE RESPONSES
Due to the homology of the KSHV vIRFs with cellular IRFs, and
the requirement of herpesviruses to inhibit immunity to establish
life-long infection, it was hypothesized that vIRFs would inhibit
the cellular pathway involved in IFN production and the anti-
viral state. vIRF expression was found to inhibit transcriptional
activation of IRF target genes such IFNα or -β, type II interferon
(IFNγ), and inﬂammatory signals such as RANTES (Taniguchi
et al., 2001). IFN-stimulated genes (ISG) often contain an IFN-
stimulated response element (ISRE) in their promoter. Several
promoter–reporter based studies have shown that vIRF1, 2, and
3 inhibit IFN-induced gene transcription. vIRF1 inhibits ISG54
promoter activity mediated by IFNβ treatment (Gao et al., 1997),
(PRD I)4-CAT activity induced by IFNα, -γ or IRF1 (Zimring
et al., 1998), IFNA4 expression induced by Newcastle disease virus
(Burysek et al., 1999a,b), ISG15-ISRE expression induced by IFNα
or β (Li et al., 1998), and IFNγ-stimulated ISRE transactivation
(Li et al., 1998). Conversely, knockdown of vIRF1 in BCBL-1 PEL
cells stimulated with IFNγ resulted in a four to ﬁvefold increase
of gamma-interferon activated sequence (GAS) and ISG15-ISRE
reporter activity, demonstrating that vIRF1 reduced IFN responses
in latently infected PEL cells (Li et al., 1998).
In addition to reporter assays, vIRF1 stable cell lines infected
with Sendai virus had reduced expression of cytokines and
chemokine RNA compared to control (Lin et al., 2001). vIRF1-
mediated blockade of IFN production has positive effects for
viral infection such as the prevention of IFNβ induction of
p21WAF1/CIP1, a regulator of cell cycle, which allows KSHV to
escape anti-viral cell cycle arrest (Gao et al., 1997).
Reporter assays also demonstrate the ability of vIRF2 to reduce
IFN-dependent transcription. vIRF2 inhibited an ISG56K-ISRE
reporter in response to recombinant IFN-α2b (Fuld et al., 2006),
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FIGURE 3 | Homology of vIRFs with cellular IRFs. Cellular interferon
regulatory factors (IRFs) are composed of a DNA-binding domain (DBD;
green) and a regulatory domain (blue). The DBD of cellular IRFs is deﬁned by 5
tryptophan (W) residues. Cellular IRFs may also contain an IRF-association
domain (IAD) shown in yellow. Gray boxes indicate domains in the cellular
IRF proteins that are homologous to each KSHV vIRF as determined by
NCBI BLAST protein analysis (National Center for Biotechnological
Information).
IRF1- and IRF3-mediated transcriptional activation of an IFNα or
ISRE promoter in virus-infected cells (Burysek et al., 1999b; Fuld
et al., 2006), IFNβ promoter activity mediated by transfection of
a synthetic double-stranded RNA and IRF3 (Areste et al., 2009),
and ISRE transactivation mediated by the IFNλ family members
IL28A or IL29 (Fuld et al., 2006). However, vIRF2 failed to inhibit
IRF7-mediated promoter–reporter activity or the IFNγ promoter
(pGAS) activity in response to IFNγ treatment (Fuld et al., 2006).
vIRF3 has been shown to inhibit transactivation of the IFN-
α4 and IFN-α6 promoter–reporter upon Sendai virus infection as
well as in the presence of overexpressed IRF3 and IRF7 (Lubyova
and Pitha, 2000; Joo et al., 2007). vIRF3 could also inhibit IFNγ
mediated activation of the GAS promoter (Lubyova et al., 2004).
Furthermore, vIRF3 expression led to the reduction of endoge-
nous IFNα1, -α4, and -α6 mRNA levels upon Sendai infection
(Joo et al., 2007), and the production of IFN following infection
with Newcastle disease virus (Lubyova and Pitha, 2000). These
data indicate that vIRF1, 2, and 3 inhibit cellular IRF processes,
including transcription and type I IFN production. In contrast to
the other three vIRFs, vIRF4 has not been shown to inhibit the
IFN signaling pathway (Lee et al., 2009b).
Studies of KSHV vIRF inhibition of the cellular anti-viral IFN
response have shown that this occurs through interaction with
cellular proteins. It was ﬁrst hypothesized that vIRF1 would asso-
ciate with the activating IRF, IRF1, as it was not yet known that
IRF3 and IRF7 are the main players in IFN signaling (Tamura
et al., 2008). vIRF1 was found to bind strongly to IRF1 in vitro,
and in cellular lysates a weak association of vIRF1 with IRF8 was
observed. Additionally, binding between vIRF1 and IRF3 was not
detected (Burysek et al., 1999a). However, others reported that
vIRF1 did not interact with soluble IRF1 in vitro (Zimring et al.,
1998). vIRF1 was also unable to interact with IRF1 bound toDNA,
although vIRF1 inhibited IRF1 transcriptional activity (Zimring
et al., 1998; Burysek et al., 1999a). Overexpression of vIRF1 blocks
binding of cellular IRF1 to DNA (Burysek et al., 1999a), and the
vIRF1 domain that shows homology to cellular IRFs was not
required to inhibit IRF1-mediated transcription (Zimring et al.,
1998). vIRF1 did not bind to IRF elements on DNA or alter the
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ability of IRF1 or IRF2 to bind DNA (Zimring et al., 1998). How-
ever, it is unclear how relevant the vIRF-cellular IRF1 interaction
is, since IRF1−/− cells do not exhibit altered virus-mediated acti-
vation of IFNα and IFNβ gene expression (Matsuyama et al., 1993;
Reis et al., 1994). The more relevant interaction appears to be the
association of vIRF1 with cellular IRF3 (Lin et al., 2001). This
interaction did not inhibit dimerization or nuclear localization
of IRF3, but IRF3-mediated transcription was blocked (Burysek
et al., 1999a; Lin et al., 2001). Although vIRF1 co-precipitates with
IRF7, vIRF1 did not block IRF7-mediated transcriptional activa-
tion (Lin et al., 2001). Additionally, the vIRFs appear to interact
with each other. In vitro, vIRF1 was found to associate with vIRF1
and vIRF2 (Burysek et al., 1999a,b). It remains unclear if vIRFs
require dimerization for functionality similar to their cellular
counterparts.
In addition to directly binding cellular IRFs, vIRF1 has been
shown to inhibit cellular IRF3 transcription through interaction
with transcriptional coactivators. Upon viral infection, cellular
IRFs recruit the p300/CBP transcriptional coactivator for efﬁ-
cient production of IFNβ (Wathelet et al., 1998). The C-terminal
portion of vIRF1 strongly binds to p300 (Burysek et al., 1999a;
Lin et al., 2001). This interaction occurs in the same region as
IRF1 binding, suggesting that vIRF1 may function through com-
petition for the binding site (Burysek et al., 1999a). It was later
determined that vIRF1’s direct interaction with p300 inhibited
p300/CBP-associated-factor (PCAF) binding to p300, and dis-
places PCAF from p300 complexes (Li et al., 2000). Furthermore,
vIRF1 competes with the active form of IRF3 for binding to CBP
on its C-terminal end (Lin et al., 2001). Expression of vIRF1 inhib-
ited IRF3 interaction with CBP in a dose dependent manner and
reduced IRF3 associationwith CBP and p300 following viral infec-
tion (Lin et al., 2001).However, vIRF1blockade of IRF3-CBP/p300
complex formation did not affect the DNA-binding activity of
IRF3 (Lin et al., 2001).
The mechanism of vIRF2 inhibition of IFN responses is not
as well characterized as that of vIRF1. The ﬁrst report on vIRF2,
in which only the ﬁrst exon of vIRF2 is expressed, demonstrated
interactions between vIRF2 and cellular IRF1, IRF2, IRF8, RelA
(p65), and p300 (Burysek et al., 1999b). No interaction with IRF3
was observed (Burysek et al., 1999b). Expression of full length
vIRF2 was found to associate with IRF3 and inhibit IRF3 tran-
scription of an IFNβ promoter (Areste et al., 2009). In this study
vIRF2 was suggested to form a multiprotein complex with IRF3
and caspase-3 and vIRF2 expression enhanced caspase-3mediated
degradation of IRF3, ultimately resulting in decreased anti-viral
responses (Areste et al., 2009). However, vIRF2 was also able to
inhibit IRF3 activity in a caspase-3 independent manner, sug-
gesting multiple mechanisms of action for vIRF2 (Areste et al.,
2009).
Similar to vIRF1 and vIRF2, vIRF3 can associate with multi-
ple cellular IRFs. Like vIRF1, vIRF3 is able to associate with IRF3,
but this requires IRF3 to be present in the nucleus, which occurs
after Sendai virus infection (Lubyova et al., 2004). vIRF3 also co-
immunoprecipitated with IRF7, independent of IRF7 activation
(Lubyova et al., 2004; Joo et al., 2007). vIRF3 expression did not
prevent IKKε phosphorylation of IRF7, or dimerization of IRF7
(Joo et al., 2007). However, the interaction of vIRF3 with IRF7
inhibited IRF7 DNA-binding, and inhibition was abolished when
the vIRF3/IRF7 interaction was disrupted (Joo et al., 2007). In
addition to vIRF3’s interaction with IRF3 and IRF7, vIRF3 has
also been shown to interact with IRF5 (Wies et al., 2009). IRF5
induces IFN transcription (Tamura et al., 2008). Expression of
vIRF3 inhibited IRF5-mediated ISRE and IFNβ reporter activa-
tion,andRNA interference (RNAi) knockdownof vIRF3 abolished
this effect (Wies et al., 2009). RNAi-mediated knockdownof vIRF3
in PEL cells produced a detectable increase of IRF5 binding to ISRE
oligonucleotides (Wies et al., 2009). These studies demonstrate
that vIRF3 inhibits IFN transcription and production through
direct association with its cellular homologs.
Viral infection activates the IRF pathway as well as the NF-
κB pathway. Activation of NF-κB following pathogen infection
results in the expression of inﬂammatory cytokines or apopto-
sis. NF-κB signaling occurs through activation of the IκB kinases
(IKKs),which phosphorylate IκB, thereby inducing its ubiquitina-
tion and degradation (Sun andAndersson, 2002). The degradation
of IκB allows the NF-κB p65 and p50 subunits to translocate to
the nucleus and initiate transcription. The NF-κB pathway is often
activated by stimuli that induce IFN signaling. Therefore, it was
expected that vIRFs could also inhibit NF-κB activity. Expression
of vIRF3 inhibited NF-κB transactivation and DNA-binding in
response to TNFα treatment through vIRF3-mediated reduction
of IKKβ kinase activity and reduced phosphorylation of IκB (Seo
et al., 2004). This was supported by vIRF3 expression resulting in
inhibited nuclear localization of p65 NF-κB subunit (Seo et al.,
2004). Furthermore, IKKβ and vIRF3 were found to coprecipitate
in 293T cells when both proteins were overexpressed, but no inter-
action was observed in BCBL-1 PEL cells (Seo et al., 2004). These
data suggest that vIRF3 may have multiple interaction partners to
effectively inhibit various immune signaling pathways. In contrast,
a NF-κB driven promoter–reporter construct, (PRD II)4-CAT,was
not inhibited by vIRF1 expression, indicating that NF-κB inhibi-
tion may be a speciﬁc activity of vIRF3 (Zimring et al., 1998).
Together, these data suggest that vIRFs vary in their ability to
inhibit the NF-κB pathway and support the notion that vIRFs
are not redundant.
In addition to inhibition of the IFN response and NF-κB sig-
naling, vIRFs have been shown to inhibit the double-stranded
RNA-activated protein kinase (PKR). PKR is activated by double-
stranded RNA and affects cell growth, cell differentiation, viral
clearance, and induction of apoptosis (Pindel and Sadler, 2011).
PKR targets include the phosphorylation of eukaryotic transla-
tion initiation factor-2 (eIF-2α) and NF-κB which control protein
synthesis and cell survival, respectively. Expression of vIRF3 par-
tially prevented PKR inhibition of protein synthesis by decreasing
phosphorylation of eIF-2α, demonstrating vIRF3’s ability to over-
come PKR translational control (Esteban et al., 2003). Inhibition
of the PKR response by vIRF3 also blocked PKR-mediated apop-
tosis, but did not affect PKR activation of NF-κB (Esteban et al.,
2003). No interaction between PKR and vIRF3 could be detected,
so the mechanism of this control remains unclear (Esteban et al.,
2003). However, an interaction between vIRF2 and PKR has been
reported (Burysek and Pitha, 2001). Expression of vIRF2 inhib-
ited the phosphorylation of PKR, and the phosphorylation of PKR
substrates histone 2A and eIF-2α (Burysek and Pitha, 2001).
www.frontiersin.org June 2011 | Volume 2 | Article 19 | 5
Jacobs and Damania KSHV vIRFs function
vIRF EFFECTS ON GENE EXPRESSION
In addition to evidence that KSHV vIRFs inhibit the host immune
response and allow for infection of the host, vIRFs have also been
implicated as transcriptional activators. As described above, vIRF1
has been shown to interfere with the formation of the CBP/p300
enhanceosome complex, which resulted in a reduction in cellu-
lar IRF transcriptional activity (Li et al., 2000; Lin et al., 2001).
vIRF1 interaction with p300 also reduces the histone acetyltrans-
ferase (HAT) activity of p300, although vIRF1 itself was not found
to have HDAC activity (Li et al., 2000). vIRF1 dependent mod-
ulation of HAT activity alters cellular cytokine expression such
as macrophage migration inhibitory factor (MIF), normally regu-
lated by acetylation of histones (Li et al., 2000). Hypoacetylation
of histones caused by vIRF1 was also observed by a reduction
in DNA staining, due to alteration of the DNA structure and its
availability to DNA dyes (Li et al., 2000). vIRF3 also interacts with
CBP/p300 in both uninfected and infected cells, through the indi-
vidual C-terminal domains of vIRF3 and p300 (Lubyova et al.,
2004).Although vIRF1 can block the association of IRF3 and p300,
vIRF3 is unable to do so. Therefore vIRF1 and vIRF3 bind to p300
in a unique manner (Lubyova et al., 2004). Furthermore, vIRF3
binding to p300 does not affect acetylation of histones (Lubyova
et al., 2004).
vIRFs have been shown to act as transcriptional activators.
When vIRF1 was fused to a Gal4 DBD to direct vIRF1 to DNA,
vIRF1 demonstrated an ability to drive transcription (Roan et al.,
1999). Indeed, vIRF1 was shown to drive its own expression
through two cis elements (Wang and Gao, 2003). Neither cis ele-
ment contains an ISRE and do not respond to induction with
IFNβ or IFNγ, suggesting that vIRF1-mediated transactivation
occurs on promoters lacking ISRE-like sequences (Wang and Gao,
2003). Similar to vIRF1, vIRF3 can also drive transcription but
through a DNA-independent mechanism. vIRF3 is recruited to
IFN-responsive promoters through its association with IRF3 and
IRF7 (Lubyova et al., 2004) and contradictory to other reports,
appears to stimulate rather than inhibit IFN-responsive genes
(Lubyova et al., 2004).
vIRFs AND DISRUPTION OF PATHWAYS ASSOCIATED WITH
ONCOGENESIS
An indication that vIRFs may be involved in carcinogenesis is
their inhibitory effects on the tumor suppressor, p53. p53 is a
key regulator of many cellular activities such as cell cycle, apop-
tosis, DNA damage response, differentiation, and angiogenesis
(Brady and Attardi, 2010). vIRF1 co-precipitates with p53 and
inhibits p53-driven transcription in a dosage dependent manner
(Nakamura et al., 2001; Seo et al., 2001). vIRF1 interaction with
p53 did not inhibit p53 DNA-binding, but resulted in a decrease
in p53 target gene expression and transcription, such as p21 and
Bax (Nakamura et al., 2001; Seo et al., 2001). vIRF1 expression also
resulted in increased levels of p53 in the cytoplasm compared to
normal localization in the nucleus (Shin et al., 2006). Initially, p53
protein levels were reportedly not decreased by vIRF1 expression
(Nakamura et al., 2001; Seo et al., 2001), although the phospho-
rylation and acetylation of p53 was reduced in the presence of
vIRF1 (Nakamura et al., 2001). However, later reports indicated
that expression of vIRF1 led to a decrease in total p53 levels, due to
vIRF1 directed ubiquitination and degradation of p53 (Shin et al.,
2006). This activity required the p53 E3 ligase,MDM2, and vIRF1
expression resulted in a reduction of phosphorylation of serine
residue 15 of p53. This is a key regulatory site that hinders MDM2
interactionwithp53. Loss of serine 15phosphorylation allowed for
increased interactionbetweenp53 andMDM2 leading to increased
ubiquitination and degradation of p53 protein (Shin et al., 2006).
Etoposide-mediated DNA damage response induction of p53 was
reduced by vIRF1 expression, and resulted in increased ubiquitina-
tion of p53 (Shin et al., 2006). Importantly, vIRF1 perturbation of
the p53 pathway also inhibited p53-mediated apoptosis (Seo et al.,
2001). Expression of vIRF1 reduced p53-mediated apoptosis from
75 to 32%, and cells that were protected from apoptosis accumu-
lated at the G2/M transition (Nakamura et al., 2001). Inhibition
of p53-mediated apoptosis may be a mechanism through which
KSHV is able to establish latency or malignancy. While p53 is
rarely mutated in KSHV-associated malignancies, treatment with
p53 activators has proved an effective treatment for PEL (Dittmer
and Krown, 2007).
In addition to vIRF1, vIRF3 and vIRF4 also interfere with
p53 signaling. Like vIRF1, vIRF3 was shown to interact with
p53, in vitro (Rivas et al., 2001). vIRF3 expression reduced p53
reporter activity in response to p53 expression (Rivas et al., 2001).
Apoptosis and activation of caspase 8 mediated by p53 was also
decreased by expression of vIRF3 (Rivas et al., 2001). However, it
is not yet clear how vIRF3 targets the p53 pathway. vIRF4 inter-
feres with the p53 pathway by interacting with MDM2 to increase
MDM2 protein levels (Lee et al., 2009b). This was accomplished
by vIRF4 inhibition of MDM2 autoubiquitination and prevention
of MDM2 proteosomal degradation (Lee et al., 2009b). Subse-
quently, higher levels of MDM2 increased ubiquitination of p53
and degradation of p53 in BCBL-1 cells (Lee et al., 2009b). Thus,
both vIRF1 and vIRF4 induce MDM2-mediated p53 degrada-
tion but through different mechanisms. Similar to vIRF1, vIRF4
expression reduced apoptosis in response to 5FU or etoposide
treatment as a result of inhibition of the p53 pathway (Lee et al.,
2009b).
Myc signaling is another pathway that is often deregulated in
human cancers and in which KSHV vIRFs have been shown to
play a role. vIRF3 increases Myc signaling by interacting with
MM-1α (Myc modulator-1; Lubyova et al., 2007), a c-Myc tran-
scriptional repressor (Satou et al., 2001). vIRF3’s interaction with
MM-1α reverses its normal suppression of Myc transcription as
measured by cdk4 promoter activity (Lubyova et al., 2007). This is
accomplished through competition between vIRF3 and c-Myc for
binding to MM-1α, which increases the ability of c-Myc to bind
to the cdk4 promoter (Lubyova et al., 2007).
The transforming growth factor-β (TGF-β) signaling pathway
is also perturbed by vIRFs. The TGF-β family regulates a variety of
biological processes including cell growth, differentiation, matrix
production, and apoptosis (Meulmeester and Ten Dijke, 2011).
TGF-β is activated by a serine/threonine kinase receptor on the
cell surface that signals to members of the Smad family including
Smad2 and Smad3, which then form a complex with a common
mediator, Smad4, and translocate into the nucleus to regulate tran-
scriptionof target genes.Viral regulationof TGF-β signalingwould
be advantageous to prevent anti-viral immunity and cell death.
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vIRF1 has been shown to interfere with TGF-β/Smad signaling.
vIRF1 inhibited TGF-β mediated transcription in reporter assays,
and vIRF1 stable cell lines were resistant to TGF-β1-induced
growth inhibition (Seo et al., 2005). vIRF1 interacts with Smad3
and Smad4 and inhibits TGF-β mediated Smad3/Smad4 DNA-
binding, as well as formation of the Smad3/Smad4 complex (Seo
et al., 2005). This results in vIRF1 inhibition of the transcriptional
activity of Smad proteins (Seo et al., 2005).
Another pathway in which KSHV vIRFs have been implicated
is the 14-3-3 family of dimeric regulatory proteins. This fam-
ily of enzymes, like many associated with vIRFs, is involved in
the regulation of cell cycle, apoptosis, and oncogenesis (Fu et al.,
2000). 14-3-3 proteins inhibit the forkhead family of winged helix
transcription factors, FOXO1, FOXO3a, and FOXO4 by seques-
tering them in the cytoplasm (Biggs et al., 1999). vIRF3 interacts
with 14-3-3s in a manner dependent on the phosphorylation of
vIRF3 (Munoz-Fontela et al., 2007). Phosphorylation of vIRF3,
the mechanism of which has not been determined, was also
required to observe an interaction between vIRF3 and FOXO3a
(Munoz-Fontela et al., 2007). It was reported that interaction with
vIRF3 facilitated the binding between 14-3-3 and unphosphory-
lated FOXO3a, which would result in decreased FOXO3a gene
transcription (Munoz-Fontela et al., 2007). For example, vIRF3
expression inhibited a G2/M arrest mediated by overexpression
of 14-3-3 through blockade of transcriptional activity. Addition-
ally, Bim promoter activation by the FOXO3a transcription factor
was inhibited by co-expression of vIRF3 (Munoz-Fontela et al.,
2007).
The hypoxia inducible factor 1 transcription factor is another
vIRF target that links vIRFs to oncogenesis. HIF-1α is a transcrip-
tion factor activated in response to low oxygen and other cellular
stressors. Upon activation, HIF-1α mediates the transcription of
target genes involved in growth, metabolism, invasion, and cell
death (Majmundar et al., 2010). These genes have been implicated
in the processes of malignant transformation and cancer progres-
sion. The most studied HIF-1α target gene is that of vascular
endothelial cell growth factor (VEGF), a secreted factor that pro-
motes angiogenesis (Majmundar et al., 2010). Through a screen of
viral genes on activity of HIF-1α inducible promoters, it was found
that vIRF3 was able to induce transcription (Shin et al., 2008).
vIRF3 increased HIF-1α transcription through direct binding and
stabilization of the transcription factor (Shin et al., 2008). This
interaction leads to increased production of VEGF and increased
tube formation in human umbilical vein endothelial cells (Shin
et al., 2008). These data suggest that the vIRF3-mediated increase
in HIF-1α transcription may contribute to oncogenesis.
The Notch CSL/CBF1 pathway has also been implicated as
a KSHV vIRF target. Notch receptors are transmembrane pro-
teins that when bound to their ligand are proteolytically cleaved
to generate the intracellular Notch fragment (NCID). The NCID
is then translocated to the nucleus and binds to the CSL/CBF1
protein. This DNA-binding factor recruits corepressor and coac-
tivator complexes to its target genes (Kopan and Ilagan, 2009).
Activated Notch signaling has been identiﬁed in KSHV-infected
PEL cells and KS cells and may contribute to cellular survival
(Curry et al., 2005, 2007; Lan et al., 2006, 2009). vIRF4 was
identiﬁed as interacting with CBF1 by yeast two hybrid assays,
and conﬁrmed by in vitro pull down assays (Heinzelmann et al.,
2010). This interaction resulted in the inhibition of NICD tran-
scription, andmay do so by competing for the hydrophobic pocket
binding site of CBF1 with NCID (Heinzelmann et al., 2010). No
other vIRFs were able to bind to CBF1 (Heinzelmann et al., 2010),
but this does not rule out the possibility that other vIRFs inhibit
Notch signaling by a different mechanism not yet reported.
Recently, vIRF3 has been implicated in the regulation of type
II interferon and type II interferon target genes. Reduction of
vIRF3 levels by RNAi in KSHV latently infected PEL cells results
in decreased transcription of IFNγ, a type II IFN to which PEL
cells are able to respond (Schmidt et al., 2011). Reduction of IFNγ
in turn resulted in reduced transcription of the IFNγ-inducible
promoter of the major histocompatibility complex class II (MHC
II; Schmidt et al., 2011). RNAi silencing of vIRF3 in BC-3 PEL cells
increased MHC II transcripts more than twofold and resulted in
increased levels of MHC II protein (Schmidt et al., 2011). MHC
II is expressed on specialized cell types of the immune system and
serves to present antigens for detection by T cells. Transcription
of MHC II is directed by the master regulator CIITA (Reith et al.,
2005). vIRF3 inhibited MHC II production through inhibition of
CIITA (Schmidt et al., 2011). Blockade of IFNγ secretion would
prohibit downstream signaling and MHC II antigen presentation,
both of which would be beneﬁcial for viral survival. It remains
unclear how vIRF3 reduced transcription of IFNγ and what effect
reduction of MHC II expression has on maintenance of latency
and survival of infected cells.
INHIBITION OF CELL DEATH
Although KSHV vIRF’s modulation of the p53 pathway con-
tributes to cell survival, there have also been reports of the inter-
action of the vIRFs with cell death proteins. Genes associated with
retinoid-IFN-induced mortality (GRIM) proteins were originally
identiﬁed due to their role in IFN/retinoic acid (RA) cell death, a
process by which administration of both factors induces apoptosis
in tumor cells (Hofmann et al., 1998; Angell et al., 2000). Yeast two
hybrid assays identiﬁed the GRIM family member GRIM19 as a
novel vIRF1 interaction partner (Seo et al., 2002). This interaction
was conﬁrmed by mammalian two hybrid, and in latently infected
BCBL-1 cells by coimmunoprecipitation and colocalization assays,
where vIRF1 and GRIM19 were seen in the nucleus (Seo et al.,
2002). vIRF1 interaction with GRIM19 reduced GRIM19 medi-
ated IFN/RA-induced apoptosis (Seo et al., 2002). Additionally,
co-expression of GRIM19 and vIRF1 in NIH-3T3 cells resulted in
a signiﬁcant suppression of transformed colonies, and suggested
that vIRF1 inhibition of GRIM19 contributes to oncogenesis (Hu
et al., 2002).
vIRFs have also been implicated in interfering with activa-
tion induced cell death (AICD) mediated by expression of the
death receptor CD95. Ligation of CD95 with its cognate lig-
and, CD95L, initiates extrinsic cell death, caspase cleavage and
apoptosis. Expression of CD95L is tightly regulated by multiple
transcription factors including NF-κB (Kasibhatla et al., 1999; Li-
Weber et al., 2000), TGF-β regulation of c-Myc (Genestier et al.,
1999), forkhead transcription factors (Brunet et al., 1999), and
IRF1 (Chow et al., 2000; Kirchhoff et al., 2002). As these cel-
lular processes are inhibited by vIRFs, it was hypothesized that
vIRFs may reduce the expression of CD95L and effectively reduce
AICD. As predicted, transfection of vIRF1 or vIRF2 reduced IRF1
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mediated induction of CD95L (Kirchhoff et al., 2002). This action
required the presence of two positive regulatory IRF1-dependent
domains in the promoter of CD95L (Kirchhoff et al., 2002). Inhi-
bition of CD95L expression resulted in decreased AICD mediated
by the T cell receptor in Jurkat T cells (Kirchhoff et al., 2002).
In addition to interfering with IFN/RA- and CD95-mediated
cell death, pro-apoptotic Bcl-2 family members, responsible for
the activation of caspases, are also affected by vIRFs. vIRF1 asso-
ciates with the pro-apoptotic BH3-only Bcl2 family member, Bim
(Choi and Nicholas, 2010). This interaction leads to the localiza-
tion of Bim to the nucleus, a location from which Bim cannot
induce apoptosis (Choi and Nicholas, 2010). This is of particular
interest as Bim is localized to the nucleus during the lytic cycle
of KSHV, and vIRF1 expression inhibited Bim-mediated apop-
tosis (Choi and Nicholas, 2010). Knockdown of vIRF1 in KSHV
latently infected endothelial cells resulted in increased cell death
compared to control and also reduced viral output upon TPA
induction (Choi and Nicholas, 2010). This suggests that vIRF1-
mediated nuclear localization of Bim protects cells from apoptosis
and thereby increases lytic viral production. Thus, disruption of
the Bim/vIRF1 interaction may have a therapeutic effect.
Expression of vIRF3 also affects apoptosis. vIRF3’s interac-
tion with PKR resulted in an inhibition of PKR-mediated cell
apoptosis, although PKR activation of NF-κB was not blocked
(Esteban et al., 2003). vIRF3 expression blocked activation of
caspase-3 downstream of PKR, but did not inhibit activation of
caspase 9 (Esteban et al., 2003). However, vIRF3 expression did
not inhibit 2-5A synthetase/RNase L system-mediated apoptosis
(Esteban et al., 2003). vIRF3 expressing cells died more readily
in the presence of TNFα than empty vector, which was demon-
strated by increased TUNEL staining (Seo et al., 2004). These data
make it unclear as to the conditions under which vIRF3 is pro-
or anti-apoptotic. TNFα treatment of vIRF1-expressing NIH-3T3
cells seemed to have the opposite effect, with reduced apoptosis
occurring in vIRF1-expressing cells compared to control (Bury-
sek et al., 1999a). Similarly, IFNα treatment of TPA-induced cells
accelerated the decline of vIRF1 protein levels and increased apop-
tosis (Pozharskaya et al., 2004). Likewise, IFNα3 treatment of PEL
cells following knockdown of vIRF3 resulted in increased activ-
ity of caspase-3/7 (Wies et al., 2009). These data suggest that loss
of vIRF or increased IFN production could lead to apoptosis in
KSHV-infected cells.
ROLE OF vIRFs IN CANCER
As discussed above, KSHV vIRFs manipulate cellular pathways
associated with the control of cell cycle, proliferation, and cell
death. Viral manipulation of these essential cellular pathways may
result in carcinogenesis. It is not surprising, therefore, that vIRF1
and vIRF3 have been implicated as possible KSHV oncogenes.
It was ﬁrst observed that vIRF1 could transform cells in vitro.
Expression of vIRF1 in NIH-3T3 cells resulted in loss of con-
tact inhibition, formation of foci prior to conﬂuence, shorter
doubling times, and higher growth rates in low serum condi-
tions (Gao et al., 1997; Li et al., 1998). The potential for vIRF1
to contribute to in vivo tumor formation was also investigated
by injection of NIH-3T3 cells stably expressing vIRF1 into mice.
These cells caused tumors in over 95% of animals with a short
latency (Gao et al., 1997). Similar experiments were performed
with vIRF2, however, vIRF2 was not able to transform NIH-3T3
cells (Fuld et al., 2006) and BJAB vIRF3 stable cells lines did not
exhibit altered morphology, growth rate, or growth in soft agar
(Lubyova et al., 2004).
The contribution of vIRF1 to continued cell growth and sur-
vival of KSHV latently infected cells was deduced in BCBL-1 cells
subjected to vIRF1 knockdown.While vIRF1 knockdown was not
particularly efﬁcient in this case, no change in growth rate was
observed compared to control (Li et al., 1998). However, siRNAs
targeting vIRF3 for destruction in PEL cells, reduced prolifera-
tion by 40% (Wies et al., 2008). This decrease in cell growth
was attributed to an induction of apoptosis upon silencing of
vIRF3 and increased caspase-3 and caspase-7 activities (Wies et al.,
2008). These data suggest that both vIRF1 and vIRF3 contribute to
the continued survival and deregulated growth of KSHV-infected
cells. To this end,Zhang et al. (2001) considered vIRF1 an ideal tar-
get for KSHV related cancer treatment and developed a ribozyme
capable of cleaving vIRF1. This ribozyme will require further
testing before it can be used as a therapeutic.
CONCLUSION
While the KSHV vIRFs share an ability to block IFN or p53 sig-
naling, each vIRF demonstrates a unique ability to block speciﬁc
cellular functions. All four vIRFs have been shown to interact with
at least one unique cellular protein (Table 1), demonstrating that
each vIRF has an individual function during KSHV infection and
latency. Why KSHV encodes for multiple vIRFs remains unclear,
although the phenomenon seems very speciﬁc for this virus. Aside
fromKSHV, only one other herpesvirus is known to encodemulti-
ple vIRFs. It is the closely related simian homolog of KSHVnamed
rhesus monkey rhadinovirus (RRV; Searles et al., 1999; Alexander
et al., 2000). Further work is necessary to determine why these
viruses encode multiple copies of genes with similar functions
and to address the requirement for vIRFs during the viral life-
cycle and their contribution to carcinogenesis. Collectively, it is
clear the vIRFs evade innate immune responses and also target
pathways related to cell survival and cell proliferation. Cellular
immune activation and apoptotic pathways are intimately inter-
twined, and by preventing immune activation and cell death, the
KSHV vIRFs activate pro-survival and proliferative pathways that
may ultimately contribute to oncogenic transformation and the
development of KSHV-associated malignancies. In addition, by
inhibiting innate immunity and apoptosis, the KSHV vIRFs play a
critical role in the survival of KSHV-infected cells, establishment
and maintenance of latent infection, and persistence of the virus
in the human population.
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